ABSTRACT
In this study, we evaluated changes in the erectile function of patients before and after transrectal prostate biopsy (TRUS-Bx) and factors that could effect this change.
In total, 126 patients who underwent TRUS-Bx for 6 months were evaluated. Those who were diagnosed with prostate cancer, those who had previously undergone biopsy, and those who were re-biopsied were not included. Values of International Erectile Index-5 (IIEF-5), International Prostate Symptom Score (IPSS), prostate volume (PV), prostate specific antigen (PSA), and visual analogue scale (VAS) were recorded before the procedure in all patients. IIEF scores recorded at 1st, 3rd, and 6th months post-procedure. Complications of disease controls were questioned and noted. At the end of the study, data were collected and statistically analyzed.
Mean patient age was 65.5±2.56 years. Initially, mean PSA value was 8.1±0.84 ng/mL, IIEF was 23.49±2.14, IPSS was 10.2±0.95, and PV was 55±4.3. The mean IIEF scores of 1st month was significantly lower than pre-biopsy values (p=0.023). Mean IIEF scores at the 3rd and 6th months were not significantly different from pre-biopsy values (p>0.05). There was no statistically significant difference in IPSS values after biopsy compared to pre-biopsy (p>0.05). The decline in the IIEF score at 1st month was independent of IPSS, PV, age, VAS and PSA values. The mean IIEF values of the patients who developed complications at the 1st month after biopsy were significantly lower than those without complications (17.8±0.9 vs 21.95±0.68).
After TRUS-Bx, erectile dysfunction may be seen in early periods. This loss of erectile function was statistically more significant in patients with complications.
Keywords: Transrectal ultrasound guided prostate biopsy, erectile dysfunction, complications of prostate biopsy
